75.00 +0.37 (0.50%)
Pre-Market: 8:26AM EDT
|Bid||74.20 x 1000|
|Ask||75.10 x 7300|
|Day's Range||74.20 - 75.20|
|52 Week Range||69.30 - 88.58|
|PE Ratio (TTM)||14.87|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||2.00 (2.46%)|
|1y Target Est||86.75|
For the first nine months of fiscal 2017, Walgreens Boots Alliance’s adjusted diluted net earnings per share increased 7.7% YoY to $3.79.
"How Moats Translate into Sustainable Competitive Advantages" is a five-part moat investing education series that explores the primary sources of economic moats.
During the first nine months of 2017 (or 9M17), Walgreens Boots Alliance’s total sales increased 0.9% YoY to $89.5 billion.
The massive online retailer with a reputation for disruption could be coming for the notoriously complex, opaque drug industry.
LONDON, UK / ACCESSWIRE / October 20, 2017 / Pro-Trader Daily takes a closer look at CVS Health Corp. (NYSE: CVS ) as the Company's stock will begin trading ex-dividend on October 23, 2017. To capture ...
Walgreens Boots Alliance (WBA) is slated to release its fiscal 4Q17 earnings on October 25. WBA's total sales are expected to reach $29.6 billion, a 4.6% increase over its fiscal 4Q16 sales.
Rite Aid Corporation (NYSE:RAD) investors certainly haven’t been faced with a shortage of things to chew on of late. The failure of Walgreen’s initial plan to outright acquire all shares of RAD stock in 2015 followed by the no-go on 2016’s revised plan to only buy 2,186 Rite Aid units — WBA is now only acquiring 1,932 of Rite Aid’s 4,560 stores — spurred mounds of investor concern, as a large cash infusion was seen as the only way to save the struggling Rite Aid Corporation. Here’s the thing: Rite Aid was in trouble, maybe even doomed, well before Walgreen’s was interested.
After shocking the grocery world with the Whole Foods purchase just a couple months ago, Amazon appears set to make another big move. Reports last week suggest that Amazon will make a final decision as to whether it joins the pharmacy space or not by Thanksgiving. The analysts at Leerink, in fact, suggest that it’s now a matter of when Amazon starts competing in pharmacy, not if.
Insurers are closing ranks around a model that brings the PBM closer to the health plan in hopes of creating a savvier buyer of prescription medicines while seeking more transparency.
Anthem’s entry is notable in a highly concentrated industry dominated by just a few large players.
The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - Kenneth I. Chenault, one of the longest-serving executives ...
Anthem plans to launch its own pharmacy-benefit manager, serviced by CVS Health, in 2020 after the conclusion of its contract with Express Scripts.
After all scoring intraday record highs, the Dow, S&P 500 and Nasdaq all set record closing prices Wednesday.
Anthem will launch its own pharmacy benefit management business, relying heavily on CVS Health for both back-end processing and retail distribution.
Anthem Inc says that it will be creating IngenioRx to act as its new pharmacy benefits manager. This will take place in 2020, which is when the company’s current pharmacy benefits manager contract expires. Anthem Inc notes that it will be combining its IngenioRx with services from CVS Health Corp starting on Jan. 1, 2020.
Health insurer Anthem Inc will start managing its billions of dollars of patient prescriptions itself in 2020, it said on Wednesday, ending a deal with Express Scripts Holding Co that had deteriorated into lawsuits over terms. Anthem said it would save $4 billion annually in the new contract with drug retailer CVS Health Corp, which will handle prescription fulfillment and claims processing starting in 2020 for five years for the new company, called IngenioRX. The new structure gives Anthem more control to lower healthcare costs, expand contracting with doctors and hospitals based on health outcomes and work on lowering annual increases in medical costs, Anthem Chief Executive Joseph Swedish said in an interview.
The contentious pricing battle between Anthem (ANTM) and Express Scripts (ESRX) has come to an end, and it isn’t with reconciliation. Early today, Anthem, one of the nation’s largest providers of Blue Cross health plans, announced it would launch its own pharmacy benefit manager, IngenioRx, in 2020 to provide services to Anthem health plans, as well as outside customers. In a separate announcement, Anthem said it has inked a five-year deal with CVS Health (CVS) to process claims for IngenioRx and fill prescriptions.
Amazon is the off-stage character dominating the on-stage discussion. Its ambition to enter the pharmacy business is well-known. But will it? Rite Aid, with 2,336 stores following the sale of its other operations to Walgreens Boots Alliance Inc. (NYSE:WBA), which would have acquired the whole company but for the Federal Trade Commission’s objections, would seem to be a natural vehicle for such an entrance.
Anthem has found a new partner to help run prescription drug coverage after the Blue Cross-Blue Shield insurer's rocky relationship with Express Scripts ends. The nation's second-largest insurer says it ...
Anthem will launch its own new pharmacy benefit management company called IngenioRx in partnership with CVS Health, effective in January of 2020.
CVS will take over services for Anthem's pharmacy benefits manager IngenioRx when Anthem's deal with Express Scripts runs out in 2020.